 |
|
U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer
February 28, 2008Thalidomide, a drug blamed in the 1950s for causing birth defects, is now showing promise as a safe and effective treatment for women with recurrent ovarian cancer, according to a study led by a University of Minnesota Cancer Center researcher.
Levi Downs, Jr., M.D., principal investigator for the multicenter, randomized Phase II clinical trial, has published the findings of this research study in the current issue of the journal Cancer. Downs is an assistant professor and a researcher of gynecologic oncology at the University of Minnesota Medical School and Cancer Center.
"For some women, ovarian cancer has become a chronic disease," Downs said. "The standard chemotherapy regimens can put recurrent cancer in remission, often more than once. However, when the cancer resists the standard treatments, we need new options for treatment."
The study compared the effectiveness and safety of the combination of thalidomide and topotecan, a chemotherapy often used for ovarian cancer, versus topotecan alone for treatment of recurrent epithelial ovarian cancer in patients who had received prior treatment. Epithelial ovarian cancer is a disease in which cancer cells form in the tissue that covers the ovary.
The study evaluated 75 women who were randomly assigned to receive either the combination of thalidomide and topotecan or only topotecan. This is the first randomized clinical trial to test thalidomide for recurrent ovarian cancer. Other clinical trials have shown thalidomide to be effective for treatment of multiple myeloma, a cancer of the bone marrow.
"We found that patients who received topotecan plus thalidomide showed an overall response rate of 47 percent compared to 21 percent response in patients who received only topotecan," Downs said. "In patients receiving topotecan plus thalidomide, 30 percent achieved a complete response, meaning the cancer went away, compared to 18 percent for patients only getting topotecan.
"Furthermore, patients getting topotecan plus thalidomide had a longer cancer-free period after treatment than those receiving topotecan alone," he said. "What all of this means is that while thalidomide may not cure ovarian cancer, it may broaden the treatment options available to physicians and provide more hope to women diagnosed with the cancer."
Ovarian cancer is the fifth most common cancer among women. This year in the United States, more than 25,000 women will be diagnosed with ovarian cancer, and about 16,000 will die from it. About 78 percent of women diagnosed with the cancer survive one year after diagnosis, and more than 50 percent survive five years after diagnosis.
The results of this study have led to the development of a new clinical trial at the University of Minnesota that will test the safety and effectiveness of a newer member of the class of drugs containing thalidomide properties for treatment of recurrent ovarian cancer.
University of Minnesota
The study compared the effectiveness and safety of the combination of thalidomide and topotecan, a chemotherapy often used for ovarian cancer, versus topotecan alone for treatment of recurrent epithelial ovarian cancer in patients who had received prior treatment. Epithelial ovarian cancer is a disease in which cancer cells form in the tissue that covers the ovary.
The study evaluated 75 women who were randomly assigned to receive either the combination of thalidomide and topotecan or only topotecan. This is the first randomized clinical trial to test thalidomide for recurrent ovarian cancer. Other clinical trials have shown thalidomide to be effective for treatment of multiple myeloma, a cancer of the bone marrow.
"We found that patients who received topotecan plus thalidomide showed an overall response rate of 47 percent compared to 21 percent response in patients who received only topotecan," Downs said. "In patients receiving topotecan plus thalidomide, 30 percent achieved a complete response, meaning the cancer went away, compared to 18 percent for patients only getting topotecan.
"Furthermore, patients getting topotecan plus thalidomide had a longer cancer-free period after treatment than those receiving topotecan alone," he said. "What all of this means is that while thalidomide may not cure ovarian cancer, it may broaden the treatment options available to physicians and provide more hope to women diagnosed with the cancer."
Ovarian cancer is the fifth most common cancer among women. This year in the United States, more than 25,000 women will be diagnosed with ovarian cancer, and about 16,000 will die from it. About 78 percent of women diagnosed with the cancer survive one year after diagnosis, and more than 50 percent survive five years after diagnosis.
The results of this study have led to the development of a new clinical trial at the University of Minnesota that will test the safety and effectiveness of a newer member of the class of drugs containing thalidomide properties for treatment of recurrent ovarian cancer.
University of Minnesota
Thalidomide Current Events and Thalidomide News RSSMolecules wrestle for supremacy in creation of superstructures
Research at the University of Liverpool has found how mirror-image molecules gain control over each other and dictate the physical state of superstructures.
Separating the good from the bad
Scientists at MIT and Brown University studying how marine bacteria move recently discovered that a sharp variation in water current segregates right-handed bacteria from their left-handed brethren, impelling the microbes in opposite directions.
Another way to grow blood vessels
Researchers at Dana-Farber Cancer Institute have found a previously unknown molecular pathway in mice that spurs the growth of new blood vessels when body parts are jeopardized by poor circulation.
Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
A new scoring system for a form of leukemia known as myelodysplastic syndrome (MDS) identifies patients who appear to have low-risk disease but actually have poor prospects of survival, researchers at The University of Texas M. D. Anderson Cancer Center report online at the journal Leukemia.
Results promising for computational quantum chemical methods for drug development
New research, led by a Virginia Tech chemist, may someday help natural-products chemists decrease by years the amount of time it takes for the development of certain types of medicinal drugs.
3-drug combination 'extremely promising' as first-line therapy for multiple myeloma
A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.
Studies attribute recent increase in multiple myeloma survival to novel therapies
Multiple myeloma is one of the most common and devastating bone marrow cancers in the U.S., but survival rates have risen dramatically over the past decade.
Northwestern chemists develop new method for synthesizing anti-cancer flavonoids
Flavonoids. You've heard of them — the good-for-your-health compounds found in plants that we enjoy in red wine, dark chocolate, green tea and citrus fruits. Mother Nature is an ace at making them, producing different ones by the thousands, but no chemist has figured out a good way to synthesize a special class of these chemicals in the laboratory. Until now.
New hope for patients with chronic lymphocytic leukemia
Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI). The results are published in the December 1 issue of the Journal of Clinical Oncology.
Keeping cancer at bay: Long-term therapy in the fight against multiple myeloma
There is no known cure for multiple myeloma, so its diagnosis means high-dose chemotherapy followed by repeated treatments with each relapse of the cancer - a watch and wait approach.
More Thalidomide Current Events and Thalidomide News Articles
 |
Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine by Trent Stephens (Author), Rock Brynner (Author) "A thoughtful account of the rise, fall, and subsequent rise again of thalidomide's fortunes."-Richard Horton, editor of The Lancet, in The New York Review of Books. In this riveting medical detective story, Trent Stephens and Rock Brynner recount the history of thalidomide, from the epidemic of birth defects in the 1960's to the present day, as scientists work to create and test an alternative drug that captures thalidomide's curative properties without its cruel side effects. A parable about compassion-and the absence of it-Dark Remedy is a gripping account of thalidomide's extraordinary impact on the lives of individuals and nations over half a century. |
 |
Beyond Thalidomide: Birth Defects Explained by Janet Mccredie (Author) How do birth defects happen? Why does thalidomide mutilate the embryo? In this challenging text the author takes a new approach to the resulting disordered anatomy and demonstrates that the skeletal defects seen are inconsistent with primary bone disease, but indicate primary damage to the embryonic sensory nerves - neural crest injury. This book will be of interest to those involved with birth defects - obstetricians, neonatologists, paediatricians - and also neurologists, scientists in teratology and developmental biology, and thalidomiders themselves. |
|
Thalidomide Ep by Brawl | |
 |
Mother with Child Deformed by Drug Thalidomide Photographic Poster Print, 24x32 by Art.com Mother with Child Deformed by Drug Thalidomide is digitally printed on archival photographic paper resulting in vivid, pure color and exceptional detail that is suitable for any museum or gallery display. Finding that perfect piece to match your interest and style is easy and within your budget! |
 |
Thalidomide Thend (Primary Contributor) |
|
Thalidomide and the power of the drug companies, (A Penguin special) by Henning Sjostrom (Author) | |
 |
The Unkindest Cut Directed By: Chris LaBonte, Steve French Also With: Steve French (Writer), Stephen Hodgins (Producer), Patricia R. Burns (Producer), Marianne Culbert (Producer), Colin South (Producer), Marlene Schmidt (Producer), Ross Hutchens (Producer), Brendan Luno (Writer) |
|
Suffer the Children the Story of Thalidomide by The Insight Team (Author) | |
 |
Thalidomide Kid by Kate, Rigby (Author) Fate dealt to Daryl from the bottom of the deck. During pregnancy, his mother took a common prescription drug that doomed him to a life without arms. But streetwise Daryl's a fighter - self-styled Thalidomide Kid superhero at heart - and he's sworn to play his rogue cards against all the odds. Kate Rigby's gritty novel follows him through a bittersweet journey of fear and determination, failure and conquest, blind prejudice . and forbidden love. For the first time in a work of fiction, Rigby lifts a corner of the veil to reveal the cruel and uncomfortable face of the thalidomide horror that crippled a generation. Thalidomide produced suicides and heroes. Daryl is a special case. You'll never forget him. Kate Rigby bravely presents grim reality in a story that pitches... |
 |
Child Crippled by Thalidomide Learns to Eat Using Her Feet at Heidelberg Orthopedic Clinic Photographic Poster Print, 18x24 by Art.com Child Crippled by Thalidomide Learns to Eat Using Her Feet at Heidelberg Orthopedic Clinic is digitally printed on archival photographic paper resulting in vivid, pure color and exceptional detail that is suitable for any museum or gallery display. Finding that perfect piece to match your interest and style is easy and within your budget! |
| © 2009 BrightSurf.com |